Home / Transcripts / Spirax Group plc (SPX) · August 12, 2025

Spirax Group plc (SPX) Earnings Call Transcript

August 12, 2025

London Stock Exchange GB Industrials Machinery earnings 60 min

Earnings Call Speaker Segments

Nimesh Patel executive
#1

Hi everyone, and thanks for being here for the presentation of Spirax Group's half year results. I'm Nimesh Patel, Group CEO, and with me is Louisa Burdett, Group CFO. Since this is an online presentation, feel free to type your questions into the Q&A box on the webcast whenever you like, and we'll get to as many as possible at the end. Let me begin with a summary of how we performed in the first half. With the macroeconomic backdrop proving challenging, we kept delivering on our operational priorities by concentrating on what we can control, generating group organic sales growth of 3%, ahead of industrial production growth, while adjusted operating profit rose 7% organically. Group margin came in at 19.3%, 70 basis points ahead on an organic basis, as we held pricing and cost discipline while continuing to invest in future growth. The demand trends I pointed to when we reported our full year results have persisted. Specifically, we're seeing strong demand growth in biopharm and semicon, together with modest IP growth and weakness in large project demand from China and Korea. In STS, organic growth was 3% once these large projects are excluded, which is well ahead of IP ex China of 1.7%, showing how our focus on direct sales in target sectors to self-generate MRO and solutions sales is driving growth.

Nimesh Patel executive
#2

Even with that sizable project-related drag, STS organic revenue matched where we stood in the first six months of last year. Over in ETS, appetite for our process heating offerings stayed robust, posting double-digit expansion during the half, and semiconductor demand likewise climbed by double digits. That vigorous demand, combined with the operational enhancements we keep rolling out — which are lifting output from our plants — produced organic growth of 10% at ETS. At Watson-Marlow, we restructured our direct sales teams around priority sectors earlier in the year, sharpening our focus on cultivating and making better use of process know-how and on forging closer ties with customers. The payoff is visible: demand growth across Process Industries sits well above IP, and on top of that we are gaining from sizable contract awards with medical device OEMs that call for delivery in the second half. Orders in Biopharm also rose by more than 10%, with shipments weighted heavily toward the back half of the year, just as we anticipated, mirroring the pattern of the demand recovery. As a result, Watson-Marlow's organic sales growth of 2% in the first half — driven mainly by Process Industries — should pick up pace in the second half, and our strong order book underpins that confidence. The restructuring we kicked off in January remains on schedule to generate annual savings of GBP 35 million, which will fund the future growth investments I will discuss in more detail later.

Nimesh Patel executive
#3

Cash conversion for the first half came in at 61%, up versus a year ago, which speaks to disciplined capital deployment and the returns we're getting on investment. Staying focused on what we can control—executing our Together for Growth strategy—is exactly how we generate organic sales growth and margin improvement amid a more volatile, uncertain economy. The progress we've made in the first half is the reason we stay confident about our outlook and the reason we're reiterating guidance today. Now let's turn to the environment we're operating in. Growth in industrial production continues to be a key lead indicator for all our businesses. And as you're aware, we outperform IP by executing our business model and strategy. This slide makes clear that the macro backdrop stayed difficult, with IP excluding China revised consistently lower for both the first and second half. The temporary bump to the H1 forecast in March reflected stronger-than-expected U.S. performance, which was subsequently revised back down in April after U.S. trade tariffs were announced. The table lays out IP for our key markets, and half of our sales come from markets where IP contracted during the first half—Germany, France, Italy and the U.K. among them.

Nimesh Patel executive
#4

And within the U.S., IP stayed soft. Our forecasts for the second half assume some of our main markets will pick up. Yet, as you would expect, our internal planning incorporates more careful assumptions, exactly as it did at the beginning of the year. When it comes to China, IP projections are still uncertain, and expectations continue to vary widely among the different providers. That is the reason we keep emphasizing IP ex China. And for the second half, IP ex China is now projected lower, at 1.7% instead of the 2.1% forecast back in February. I will now walk you through 2 significant growth drivers for 2024: how this soft backdrop and political instability affect demand for large projects, along with the demand trends we are observing in biopharma. STS sales came in organically flat versus the first half of 2024 after, as anticipated, we encountered substantial headwinds in China and Korea. Those markets represent roughly 20% of STS sales and 10% of group sales. As you are aware, both derive a larger share of sales from large projects funded through customers' capital budgets. Not surprisingly, given uncertainty surrounding tariff barriers and costs to global trade, business confidence has taken a hit and longer-term capital investment decisions have been pushed back.

Nimesh Patel executive
#5

Back in China, we flagged this pressure point at the start of 2024, and we laid out how we shifted toward generating MRO and solution business from the big installed base. Twelve months ago, China had zero sales engineers focused solely on MRO. Today that number stands at 20, and we're adding more. Site visits are up by close to 10%. Customers are responding. We posted double-digit growth in those sales across full year 2024 and once more in the first half of this year. So even though demand overall in China keeps shrinking, the pace of that shrinkage is easing. We believe capital project demand will level off and afterward resume growing. Along with ongoing gains in MRO, we foresee a route for China to contribute to STS growth again at some point in 2026 or 2027. In Korea, macro difficulties were made worse by political turmoil. That produced a sharp drop in demand during the first half, once more especially in large project orders. With elections behind us and an economic stimulus package proposed, we expect better demand in the second half. We observed a sequential rebound, with the second quarter ahead of the first, and that carried into July and August. Our sales pipeline kept expanding in the first half as well, particularly in Q2, which tells us customers are postponing investments rather than scrapping them.

Nimesh Patel executive
#6

Combined, first-half revenue in China and Korea fell 9% versus a year ago. For the second half, we expect absolute demand from China and Korea to match the first half. Now, if we turn to STS's underlying performance, the chart on the left shows that, once those large project sales are excluded, STS sales rose organically 3%, against IP ex China of 1.7%. That clearly shows our business model working, reinforced by carrying out our Together for Growth strategy, which I'll come to later. Turning to another key demand driver, biopharm, which represents nearly 50% of Watson-Marlow sales and 12% of group sales. We keep seeing a robust rebound in biopharm demand following the COVID vaccination downturn, when new order intake halved from 2021 to 2023. As we explained in March, sales from 2022 to 2024 were propped up by drawing down the very large backlog accumulated over COVID, with customers rephasing shipments instead of canceling them. By the end of last year, our order book had normalized. Through the first half, and continuing last year's trend, end-user demand grew strongly, and we are now also seeing OEM demand recover, which previously had been highly volatile.

Nimesh Patel executive
#7

During the first half, biopharm orders increased by more than 10%, after also achieving double-digit growth in 2024. Orders have once again moved ahead of sales, and that gives us confidence in sales growth for the second half. With those market-related demand drivers covered, I'll pass things to Louisa, who will walk you through our first half financial performance in greater detail, after which I'll give an update on how our strategic progress is going.

Louisa Burdett executive
#8

Thanks, Nimesh, and good morning, everyone. Before we begin, there are a couple of housekeeping items that should be familiar to you. The figures we'll be talking about today are the adjusted results, and you'll find a reconciliation between statutory and adjusted operating profit in the appendix. Also, since there was no material M&A during the period, our definition of organic growth only strips out the impact of currency movements on sales and profit, and in the first half that effect was minus 3% on sales and minus 7% on operating profit. So trading in the first half came in line with the expectations we laid out in May. At the group level, on an organic basis, revenue rose 3% compared with the prior period, ahead of IP and driven by growth in ETS and Watson-Marlow, while STS was flat year on year. Operating profit was up 7%, with operating margin 70 bps higher at 19.3%. Net financing costs came to GBP 18.6 million, below the prior period thanks to lower average net debt and lower rates on floating debt. As we expected, the effective tax rate was 27.4%, and adjusted EPS of 137.6p per share was flat versus the prior period, in line with the modest decline in operating profit and the rise in the effective tax rate, both of which were offset by reduced financing costs.

Louisa Burdett executive
#9

Our interim dividend is going up by 3%. Now let's look at the sales bridge on the following slide. As we mentioned, currency fluctuations hurt first half sales by GBP 28 million, which is 3%. In Steam Thermal Solutions, organic sales were flat versus the first half of 2024. Solid increases in MRO and solutions revenue made up for the weakness we expected in large CapEx aligned projects in China and Korea. And as you've already heard, if you adjust for those large projects in China and Korea, the remainder of steam achieved 3% growth even with the soft IP environment. ETS delivered 10% organic sales growth in the first half, which reflects continued operational gains in process heating, a contract win with an OEM supplier of temperature management solutions for data centers, and better semicon demand in equipment heating. Watson-Marlow posted 2% organic sales growth, helped by above-IP growth in Process Industries, with biopharm roughly flat against 2024. Double-digit order growth in biopharm during the first half, with shipments weighted toward the second half, will support stronger sales in the second half, and that matches the shape of the biopharm demand recovery we had anticipated. The bridge on the following page breaks down the changes in adjusted operating profit for the first half.

Louisa Burdett executive
#10

Currency fluctuations took a toll, costing us GBP 11 million, or minus 7%. In Steam Thermal Solutions, operating profit was up 3% organically, outpacing sales growth, and that came from manufacturing efficiencies as well as savings delivered by our restructuring program before reinvestments that are weighted toward the second half. The Steam operating margin of 23.4% was 60 bps stronger organically than in the first half of 2024. Over in ETS, operating profit rose 12% organically on the back of higher volume and ongoing efficiencies in process heating. The ETS operating margin climbed 60 bps organically to 15.3% prior to adjusting for a one-off 30 bps negative currency movement tied to the U.S. tariff announcements in April. As we pointed out in the 2024 full year results, we are still working through some legacy orders in the Ogden pipeline that have not been repriced for inflation, and that held back the first half margin against the backdrop of strong sales growth. Even so, the ETS margin improved steadily across the first half, supporting a stronger margin trajectory as we move into the second half. Watson-Marlow posted organic profit growth of 12% along with a 240 bps gain in margin. Beyond volume, the trading margin improvement came from manufacturing efficiencies and, as with STS, from delivering some net restructuring savings ahead of reinvestment.

Louisa Burdett executive
#11

Corporate costs stayed at roughly 2% of group sales, and that figure includes spending on key strategic initiatives in digital and sustainability. Now, on to cash flow. Our rate of converting operating profit into cash came in at 61%, which is higher than the 53% we saw in the prior period, and the improvement came from a smaller working capital outflow as well as reduced capital expenditure. Even with GBP 13 million of cash spend tied to restructuring, we managed to post a modest rise in cash flow versus the prior period and to bring net debt down. So we finished the first half sitting at GBP 658 million of net debt, with leverage at 1.8x EBITDA. CapEx came to GBP 34 million, equal to 4% of sales, and I want to highlight 3 quick points of interest. During the first half, GBP 7 million went toward finishing our new low and medium voltage production facility in Ogden, which is due to be commissioned for use shortly. On ERP, our focus right now is on common design and build ahead of deploying CapEx through each business unit. And, as we mentioned at the full year results, we have put a pause on the planned expansion of our Gestra facility in Germany. We have begun a formal process with the local works council to look at ways to reach greater efficiency and better performance.

Louisa Burdett executive
#12

Moving to the next slide, I'll walk you through our view of how the second half is taking shape. Broadly, we anticipate an acceleration during the second half, driven by the robust order books we had at the close of the first half, ongoing recovery in key end markets, and additional progress on our operational priorities. On steam in particular, Nimesh will speak shortly about how our growth initiatives in MRO and distribution partnerships have succeeded, and those will carry on through the second half. Crucially, in China, we expect the drop in large projects to begin easing during the second half. We also anticipate better trading in Korea now that the political situation there is stabilizing, as indicated by stronger order growth in Q2 compared with Q1. For STS margin, our expectation is that the second half will look like the first half. Within ETS, we anticipate additional gains in throughput in process heating. Revenue is weighted toward the second half on volcanic projects, and we will see more benefit from the semicon upturn in equipment heating as well. All of this will underpin sales momentum as we move through the second half, though I would remind everyone that the comp we face is much tougher than in H1.

Louisa Burdett executive
#13

For 2024, organic growth in the second half came to 15%. As I said before, the ETS margin rose steadily across the first half, and we anticipate a bigger margin in the second half thanks to drop-through, favorable mix and a modest net restructuring gain. At Watson-Marlow, we expect stronger sales conversion in biopharm during the second half, since orders are running above sales and OEM trends are leveling off. Within Process Industries, we hold a fairly sizable customer order in medical equipment carrying specified H2 delivery dates. More broadly, though, the Process Industries team is generating growth that outpaces IP. With the reorganization complete, our sales teams now get better support to build deep expertise in their customers' processes and to capture the most opportunity from accounts offering the greatest potential. Setting up an inside sales team dedicated to smaller customers and less complex orders has likewise freed sales engineers to visit customers more often, and that is producing double-digit demand growth across sectors such as wastewater, mining and medical. For Watson-Marlow in the second half, we expect margin roughly matching the first half, with added gains from manufacturing efficiencies and drop-through on higher sales, which lets us increase investment in future growth.

Louisa Burdett executive
#14

Regarding the group, the tariff situation is still unclear, though we anticipate continuing to offset the financial effect via surcharges, pricing, and a modest reorganization of manufacturing operations. So on my final slide, moving to guidance. Our guidance at the group level for the whole year is still the same. We still anticipate organic growth in group revenue consistent with 2024. And we still anticipate mid-single-digit organic growth in adjusted operating profit. We have set out in the RNS and in today's presentation the expectations by business unit for sales and margin, which align on a full-year basis with the guidance provided in March and which we are reaffirming today. The P&L charge for our restructuring program is still the same at a total of roughly GBP 40 million. But the cash outlay will be distributed across 2025 and '26. Other group guidance factors appear in the appendix of your pack. And just briefly, CapEx guidance is comparable to the first half at 4% to 5% of sales. We are guiding for lower net financing costs than previously guided, and our current FX outlook is unchanged from the May trading update at minus 3% and minus 6% on sales and profit, respectively, for the year.

Louisa Burdett executive
#15

Now I'll return things to Nimesh for the remainder of the presentation.

Nimesh Patel executive
#16

Thanks, Louisa. Now I'd like to discuss the way we're carrying out our strategy. This slide should look familiar—you saw it during our full year presentation. The gains we achieved in sales and profit during the first half, even with macroeconomic difficulties, stem from what this slide lays out. Three robust growth engines sit at the heart of our business, each drawing on the same potent model built around our seasoned direct sales engineers, who draw on local ties with more than 100,000 customers across close to 70 countries and bring in revenue mostly from OpEx-funded budgets in sectors that are largely defensive. Our medium-term targets are clear, along with a plan to hit them via our operational priorities, namely: commercial excellence—how we strengthen our sales capacity and capability; operational excellence—how we boost productivity and efficiency in manufacturing; and organizational fitness—how we refine how we work throughout the organization so we serve customers better. Through these, we can make better use of our resources and help finance focused investments in future growth via digital and services and decarbonization, which will in turn help us meet long-term targets. With this framework, we laid out our particular areas of focus at the full year results.

Nimesh Patel executive
#17

I wanted to revisit those points and give you an update on how we've done in the first half, along with a handful of examples of delivery. Let's begin with commercial excellence. During the first half, we concentrated on producing MRO and solution sales across all 3 businesses, backed by sales engineers who walk customers' plants to spot optimization opportunities, and strengthened by building out our digital connections and systems audit capability — both of which bring in service revenues and also pull products through. At STS, we're additionally reshaping how we partner with distributors, with the goal of drawing on the expertise of our direct sales engineers to generate solution sales from new target customers. At Watson-Marlow, we're achieving double-digit demand growth thanks to the successful sectorization of our sales engineers, who historically were focused geographically, as Louisa has explained. In ETS process heating, our bespoke heating solutions, including our medium voltage offer, remain a differentiator and are supporting double-digit demand growth, including from decarbonization-related orders, which I'll cover later. Moving on to operational excellence. Louisa has told you that we're achieving operational efficiencies within and across our 3 businesses, generating benefits in material usage, procurement and labor productivity. We're also carrying out the consolidation of manufacturing facilities, including finishing the closure of our STS facility in Mexico and moving production to the U.S.A.

Nimesh Patel executive
#18

Within ETS, we keep pushing operational gains, especially at Chromalox, where throughput during the first half has been raised successfully and now stands more than 25% above where it was in 2023 — clear evidence of the strides made both last year and this year. You've also heard how organizational fitness is advancing: restructuring is well along and tracking to plan, and the savings it produces will support what we invest in future growth. Next slide, I'll walk you through 3 instances of commercial excellence. First, a U.S.A. case, where STS has rethought the way it engages distributors, who account for roughly 70% of local sales. By approaching partnership differently, we now co-create opportunities that speed up growth, setting joint go-to-market strategies for sectors and customers we target together. Solid growth plans are now agreed with 8 key distributors. During the first half, those partnerships delivered 20% growth in orders. More such arrangements are in the pipeline for the second half. Direct sales plus co-created opportunities represent approximately 50% of total U.S. demand as things stand. The second case on this slide, from ETS in Mexico, shows how pairing commercial with operational excellence allowed us to serve an OEM customer through a bespoke solution for an essential component destined for data center temperature control.

Nimesh Patel executive
#19

Our sales and supply teams collaborate closely, pairing solution selling with manufacturing that's both responsive and flexible, to pull off a successful pilot—which has since turned into a material contract win. To handle the order volumes that will underpin growth in the second half and beyond, we've established a production line that is bespoke and dedicated. The third example shows how the sectorized approach at Watson-Marlow is driving growth. In the U.K. wastewater sector, we supply peristaltic pumping solutions to OEMs and directly to customers, which calls for a multilayered approach to engagement. This sector is highly regulated, with utility companies obliged to use precise chemical dosing to keep water quality up. Historically, regulation specified only diaphragm pumps. Our wastewater team engaged key industry stakeholders, helping them develop new mechanical and electrical specifications that now include peristaltic dosing pumps, which opens up additional revenue streams. As an illustration of the impact, sales from just one chemical customer that switched to our Qdos pumps grew 60%, with more to come. Those are some of the drivers behind our near-term growth. Now I'll talk about how we're building on our foundations to accelerate long-term growth. Through our digital and services growth driver, we strengthen customer relationships by being more connected with them—we walk the data as well as walk the plant.

Nimesh Patel executive
#20

During the first half, we hooked up another 400 customer sites, which gives us live data on their crucial processes and brings the overall count to 1,400 sites. Information coming from our connected offerings — things like steam trap monitoring and pumps with machine learning built in — is fueling pull-through revenues across service and product lines. On top of that, we're boosting the amount of time direct sales engineers spend in front of customers. After wrapping up a pilot last year, we've now widened both the sectors and the scope covered by our AI knowledge assistant, MiM, so it applies more broadly. Today it's being used actively in support of sales engineers, and on average it saves each of them more than 4 hours every week — chiefly on researching particular production processes or product applications and on developing solutions. Turning to decarbonization. As you'll recall, we discussed our opportunity of almost GBP 7 billion during our last Capital Markets presentation. That represents a 60% rise over the annual addressable market we have now. So how was this figure arrived at? The first piece is electrification of steam generation, which we size using the current installed base of fuel-fired boilers across our target sectors and regions. Our assumption is that adoption will unfold over decades, held back by things like customers' willingness to invest, the availability of green electricity, and grid transmission capacity. Even so, that still amounts to an annual addressable market of GBP 2.4 billion.

Nimesh Patel executive
#21

Second, we have the decarbonization of thermal energy past steam — that is, the portion of industrial process heat that lends itself to electrification. To gauge the size of it, we drew on our knowledge of sectors and processes to pinpoint the industrial heat applications now served by burning fossil fuels directly. For those applications our electrification technology can serve, given temperature and power load requirements, we translate total heat demand into the heating power we estimate would be needed to meet it. The resulting demand, as you can imagine, is enormous, and since this transition is a long-term endeavor, we have built in a lengthy, multi-decade conversion. We put the potential market at GBP 4.2 billion annually. Let me now explain how we are positioning ourselves for this market and what customers are telling us today, because although we recognize the headwinds to adoption — particularly in a cost-focused environment — we do keep seeing demand. This slide shows how we partner with customers to optimize, manage and ultimately decarbonize their thermal energy processes via 4 go-to-market strategies. Beginning at the left and moving right: energy optimization has always sat at the core of our customer value propositions in STS and ETS, with our teams helping customers become more efficient by cutting their energy consumption, which in turn makes them more sustainable.

Nimesh Patel executive
#22

At this point, more than 50% of STS quotes contain quantified sustainability benefits from the solutions we propose. Moving on, our new-to-world Target Zero solutions come from a unique blend of expertise in steam and electric thermal energy, and they're built to electrify steam generation. We've reached agreement with a number of global industrial boiler OEMs to incorporate steam vault technology into their electric boilers, with our first pilot solution installed at a regional food and beverage customer facility and a second solution planned for delivery and installation at a chemical plant in the second half. ElectroFit, which makes it possible to convert existing fuel-fired boilers to electric, is being tested and refined with a global food and beverage customer at 2 production sites. Turning to PoweringZero, which uses our low voltage and proprietary medium voltage, or MV, technologies to replace the direct burning of fossil fuels. After a successful pilot to build a decarbonized model of an OEM machine serving the paper industry, we're working on our first orders from this leading manufacturer, and we also recently secured an order for a bespoke MV solution for a renewable energy storage project. We're testing prototypes for the next generation of electric heating solutions that operate at higher voltages and higher temperatures, which have the scope to further differentiate our competitive position while also expanding our addressable market beyond our current assessment.

Nimesh Patel executive
#23

To wrap up, I'm glad about what we achieved during the first half in creating our integrated capability for assessing steam and electric thermal energy, supported by a seasoned group of audit specialists pulled from STS, ETS and <<inaudible>>. We're running pilots for clients in the sectors we target — food and beverage, downstream petrochemicals and chemicals — which confirms customer interest in a combined, holistic review of their thermal energy requirements spanning steam and electric, and reflects our deep, distinctive blend of expertise. Now that I've laid out what I hope you'll see as promising prospects ahead, let me return to our emphasis on the first half. Tying it all together, here's how I'd characterize our performance: first-half results came in as we expected, since we keep confronting the macro headwinds by carrying out our strategy and concentrating on what we can control. Across our 3 businesses we're generating demand growth by executing our strong business model, and throughout the group we're pushing operational enhancements. As a group, we keep producing organic growth that beats IP at margins that lead the industry. And the changes to our organization are freeing up the funds to invest in speeding up future growth. For the rest of the year, we don't anticipate any meaningful improvement in the trading environment.

Nimesh Patel executive
#24

Even so, our confidence in hitting our operational priorities hasn't wavered, and that's the reason we're reaffirming guidance for the full year, which stands unchanged. With our Together for Growth strategy, we're constructing a platform that will let us achieve our medium-term financial objectives as well as long-term compounding growth at appealing margins. Thank you. At this point we're glad to take your questions. If you haven't yet posted them into the platform, please do that now. Mal, our Head of Investor Relations, is watching the questions come in and will put them to us on your behalf. So, Mal, the floor is yours.

Mal Patel executive
#25

Alright, thanks to all of you for sending in your questions through the portal. To make this useful for everybody, I'll try to sort them into specific businesses or topics. I think that will work best for you. So there are a few questions for the team about Watson-Marlow. First, since you're expecting stronger volumes in the second half, could you give us some detail on the investments you have planned that would offset operating leverage at Watson-Marlow during that period?

Louisa Burdett executive
#26

Yes, Mal, I’m able to take that question. We have consistently said that the savings from our GBP 35 million annual restructuring program get reinvested, with a large portion going back into the business. That’s the reason we don’t expect second half margins to be materially higher than the first half, even with higher volumes. The investment is being made in Watson-Marlow, and it’s common across the group, but we’re directing money toward commercial sales headcount, new product development, and digital as well as systems improvements. I think it’s fair to say, though, that we remain confident this division returns to a 30% margin. It is well invested, and we would expect the volume drop-through to deliver that over the medium term.

Mal Patel executive
#27

Could you share some insight into what you're observing on the OEM demand side, and in particular, is there any shift between consumables and nonconsumables OEM demand within Watson-Marlow?

Nimesh Patel executive
#28

Just to remind everybody, end users make up roughly 75% of biopharm demand, while OEMs represent 25%. As we mentioned a year ago, we've observed particularly robust growth in end-user demand, and that has carried on through the first half. Now, we serve a very large number of end-user customers. So it isn't a surprise to see variation in the demand across that whole spectrum of customers, but it lines up with what we'd anticipate given the underlying growth of the biopharm markets. On the OEM side, the difficulty we encountered last year was volatility. It's a limited set of accounts, and demand can swing quite a bit from one account to another and, in fact, even for a given account from 1 month to the next. That said, during the first half of this year, we've seen that volatility come down and overall demand from OEMs rise. And taken together, end-user demand plus OEM demand is what has produced over 10% growth in orders in biopharm.

Mal Patel executive
#29

And then last, regarding Watson-Marlow for the time being at least, could you walk us through the specific actions you're taking in order to shift portions of production over to Devens, and what effect that could have on costs and margins?

Nimesh Patel executive
#30

Yeah. So the timing on our new Devens facility in the U.S. has worked out well, considering what's going on in the U.S. especially with tariffs. Moving production into Devens has been our plan all along so we can serve the domestic U.S. market, and those plans are continuing and we're speeding them up. Devens has full capability, including clean room capability that can help produce our single-use product portfolio serving the biopharm industry. So what are we doing concretely? Well, we began last year by training our teams locally in Devens, drawing on the expertise at our Falmouth plant in the U.K., and we've kept that going. We're clearly raising headcount through local hiring, and we'll keep up those activities so that more of our domestic demand in the U.S. is supported from Devens as time goes on.

Mal Patel executive
#31

I have a couple of questions about Gestra. Could you provide a little more detail on the restructuring you're considering at Gestra? And does that reflect the weaker trading outlook for the business, or is it more about you relocating capacity?

Nimesh Patel executive
#32

This isn't tied to the trading outlook for the business, apart from the difficulties we're encountering more widely in a softer IP environment. As I mentioned earlier, our focus has been on operational excellence—which really means getting the most value possible out of the manufacturing footprint we already have. And in reviewing that footprint, we've identified ways to be more effective and more efficient, which in the end helps us, yes, to save money, but also to serve our customers better. So right now we're exploring with the Works Council in Gestra how we can be more efficient and more effective at Gestra, serving our customers better and thereby accelerating growth in that business. We'll keep doing this in every part of our business, across all of our manufacturing facilities around the world. To me, this is normal behavior in the manufacturing environment now.

Mal Patel executive
#33

Still on steam, let's turn to China steam. Could you give us a sense of how large project sales specifically in China performed during the first half, and how MRO growth looked? And connected to that, what makes you confident that the weakness you're seeing in China will moderate in the second half?

Nimesh Patel executive
#34

Sure, I'd imagine it won't come as a surprise to anyone that big projects funded out of customer CapEx budgets have taken a hit from weaker business confidence amid a more uncertain economic climate, and that's been driven in no small part by uncertainty surrounding tariffs. For us, China and Korea have felt that driver more heavily, partly because while across steam overall 85% of our sales come from OpEx budgets and 15% comes from CapEx budgets, in China specifically roughly 60% of sales come from our customers' CapEx budgets. So what we've observed in China is a drop in that large project demand. At the same time, MRO has grown double digits. China overall was down, and as we said in our presentation, China and Korea combined were down 9%. So I think from that you can deduce that large projects in China would have been down double digits. What pleases us is the moderating of that decline that we're seeing sequentially in the first half of this year and, indeed, in the second quarter of this year compared with the first quarter. So in China we're seeing a smaller decline versus prior year as time goes on.

Nimesh Patel executive
#35

That's also being counterbalanced by MRO’s ongoing double-digit expansion. In Korea, demand is rising sequentially from Q1 to Q2. That pattern carried through July and August, and it gives us confidence that after the elections in Korea and the proposed economic stimulus, large project demand there will recover in the second half of the year. Still, overall we’re not getting carried away. Our call is for combined China and Korea sales in H2 to be flat versus H1, and that will support our second half steam growth.

Mal Patel executive
#36

And then, still on China and Korea — since exposure to big projects in those 2 markets is what it is, how do you view the cadence of MRO opportunities coming out of that large installed base?

Nimesh Patel executive
#37

Honestly, the MRO possibilities strike us as genuinely thrilling. As I've mentioned previously, what sets us apart in that space is our direct sales engineering team, the relationships we hold locally with customers, the sector-based approach we take to serving them — and because of that, we can walk the plant and spot optimization opportunities. So let me be clear: our competitors aren't able to do that the way we do. As attention grows on extracting more from the installed base — and incidentally, I don't mean only our own installed base, but the entire steam installed base across China — that opens enormous opportunities for our sales engineers, and we're already seeing it happen. So the double-digit MRO growth I mentioned a moment ago doesn't stem solely from our installed base. It also comes from displacing competitors' products at customers we haven't served before, while simultaneously finding new and additional sectors we can keep addressing. So I believe this leaves us with a stronger business in China going forward. And keep in mind, both China and Korea rank among the 2 highest-quality, highest-margin businesses we have, within steam and within our group.

Mal Patel executive
#38

Next up, ETS. Could you elaborate a little more on what drove the double-digit growth in semicon? Does that reflect market improvement, or is it something specific to what you do?

Nimesh Patel executive
#39

Yes. So in semicon, we're a niche player — for instance, not only in atomic layer deposition for wafer fabrication equipment, but in thermal atomic layer deposition specifically. A niche within a niche. We have a handful of large customers we work very closely with, all the way from R&D through to production of their equipment. So what we're seeing is specific to our business, those R&D programs and our customers' success. And we've said semicon demand improved in the first half, but remember, off a reasonably low base. So there's further to go there. What's encouraging here is how this supports our journey to delivering on our ETS margin of 20%, which we've also said and always said will be nonlinear. So there are 4 factors which will get us to that 20% margin. The first is a recovery in semicon demand because that is higher-margin business for us. The second is the increasing throughput in our manufacturing sites to be able to pull down on our strong order books. And I talked earlier about the fact that in Chromalox, we've seen a 25% increase in throughput versus 2023. The third is clearing some of our legacy orders, particularly in the industrial process heating part of our business and in Ogden, the larger bespoke projects that we have.

Nimesh Patel executive
#40

We also moved that forward again during 2025, though additional work remains over the rest of this year. And last, ETS presents us with a genuine pricing opportunity. Semicon, then, represents merely one piece of that overall journey.

Mal Patel executive
#41

To follow up on what you said, you mentioned legacy orders and discussed how they affected margin during the first half. Could you share where things stand on working those off, and whether they'll be fully cleared by the end of this year?

Louisa Burdett executive
#42

Thanks, Mal. Yes, we still have certain legacy orders that remain profitable for us, but we haven't been able to reprice them for inflation. Those orders have moderated the margin in the first half. However, as we said at our full year results, we expect to clear them by the end of 2025.

Mal Patel executive
#43

Could you give us some more detail on that order you got from your data center OEM? What exactly does it involve? How much did it add in the first half? What do you see it providing in the second half? And should we be looking for more of these? Or do you view it as a headwind?

Nimesh Patel executive
#44

I think the data center order is a great illustration, as I mentioned earlier, of how our sales and supply teams are collaborating, opening up new sectors, and it shows the strength of our ETS business in industrial process heating — specifically, through our ability to design and deliver thermal energy solutions, in this instance electric thermal energy solutions, thanks to our deep expertise. So it really sits in the sweet spot of what we do in ETS. To put it in context, industrial process heating demand grew double digits in the first half. If we took out this larger order, growth would still have been significantly above IP, okay? So I wouldn't read too much into that single large order on its own. But again, a pleasing example of what we're doing in ETS, and it will support our second half sales growth.

Mal Patel executive
#45

Changing direction slightly. Louisa, can you provide a little more detail on how you anticipate your restructuring cash and noncash costs will be divided between this year and next year? And along the same lines, could you tell us a bit more about how you expect the cost savings to be phased in? And what do you think a rough guide might be for the first half versus the second half?

Louisa Burdett executive
#46

We're making solid progress on the restructuring program we announced at the close of last year. Our goal was to achieve GBP 35 million in annualized savings, and we remain on track to hit that. The cost envelope needed to deliver it is unchanged at GBP 40 million. Most of that will hit our P&L this year, we expect. But of course, since we're rolling this out at varying paces across 2025, the cash outlay will spill into 2026. We figure roughly 70% in '25 and 30% in '26. So when you're building your cash flow models, that's likely a useful heuristic for the restructuring costs.

Mal Patel executive
#47

All right. And could you go over your full-year guidance once more for us — both interest costs and CapEx relative to sales?

Louisa Burdett executive
#48

Regarding CapEx relative to sales, the percentage for the half year came in at 4%, and for the full year we're guiding to a similar range of 4% to 5%. That is a bit below the guidance we gave at the full year. As for interest costs, we guided GBP 44 million for the full year. We now expect that figure to be around GBP 40 million. It's also worth noting that the team has devoted considerable time to focusing on cash performance, making sure more cash is being pulled to the center. And as I mentioned in my script, covering the restructuring costs within an improving cash position. So we're pleased with this.

Mal Patel executive
#49

And while I have you, Louisa, could you update us on the ERP rollout status? How much longer do you expect it to take? What's our view on the total cost of the rollout, and so on?

Louisa Burdett executive
#50

We're still at a fairly early point in this. Across the 3 business units and corporate, we're working on one common design. That should wrap up around November, and after that we'll move into a phase of common build. As reassurance for listeners, let me repeat what Nimesh and I shared at the Capital Markets Day: our rollout will be handled in a considered way, with some parameters set around how much we spend annually and the risk — the revenue at risk — that we'd be covering. Right now we don't have a total program cost, but we'll give you an update on that as we move through the full year.

Mal Patel executive
#51

Now, circling back to steam. Nimesh, you mentioned expanding the number of dedicated MRO salespeople in China. What target do you have in mind? And how should we think about what it will take to invest in adding more dedicated MRO engineers?

Nimesh Patel executive
#52

Right. So the size of our engineering team will be determined by the opportunities we keep pursuing inside China. But I have no doubt whatsoever that this engineering group will grow beyond 20 people over time. We need to strike the proper balance between concentrating on large projects, once that demand begins to recover, and concentrating on MRO. As for how this increase gets funded, it will come from the programs we have already discussed. So first, as demand returns, as we push sales and seek to plow the advantages of the drop-through back in, we will grow our headcount. And second, as we get more efficient in how we operate the business — in manufacturing, for instance — and we have shown the decrease in procurement costs and material usage. We have produced ongoing improvements at our manufacturing sites, which, incidentally, has led to better margins across all 3 businesses in our manufacturing activities during the first half. As we achieve that, we will put those benefits back into the various growth opportunities we have throughout our group, judging them on their relative merits and the returns on investment we are able to generate.

Mal Patel executive
#53

Let me return to Watson-Marlow and how we ought to frame your mid-single-digit organic growth for the full year. That means high single-digit growth in the second half. Do you expect that to be — how would you expect that split between process industries and biopharm?

Louisa Burdett executive
#54

Exactly, that's right. For the full year, our guidance for Watson-Marlow is mid-single-digit growth, and that points to high single-digit growth in the second half. We anticipate that process industries will keep performing above IP, which means biopharm comes in higher. Yet if you look at the key KPIs we've been discussing in biopharm, orders sit above sales, and we've said all along that this would be a critical point for a second half recovery. So process industries above IP growth, bio slightly higher, delivering high single digits in the second half for the full year, mid-single.

Mal Patel executive
#55

Also still on biopharm — could you give us a sense of how far away you believe you are from demand returning to normalized levels?

Nimesh Patel executive
#56

My view is that the recovery has more room to run. So when I look at the run rate for end user demand, I feel confident that among that group we're nearer to having recovered. On the OEM side, volatility has come down. We've seen a solid improvement, though it comes off a low base in demand. Still, I believe OEM demand has more recovery ahead.

Mal Patel executive
#57

Then circling back to the guidance you gave for the whole year — you mentioned China, Korea, and IP as still carrying risk. What's the right way for us to frame how you see overall macroeconomic conditions?

Nimesh Patel executive
#58

Macroeconomic conditions will probably stay volatile, uncertain, and possibly difficult. I believe that shows up in the IP forecasts, and it also shows up in the news we read each morning when we get up. At the same time, we aren't excessively focused on developments in IP or in the broader macro picture, because one thing that makes me proud of how we performed as a group in the first half, and of what our colleagues are delivering, is our capacity to concentrate on the opportunities we identify in our markets and in the geographies we serve. China pursuing MRO demand is, I think, a strong illustration. Distribution across the U.S. and the way we are reshaping our model is another strong illustration. I mentioned wastewater and what we have accomplished there through sectorization at Watson-Marlow in EMEA. And naturally, we discussed the data center order at ETS. So opportunities exist. Executing our strategy therefore means ensuring we take the steps within our control to generate our own growth even when conditions are tougher. Are we immune to a difficult environment?

Nimesh Patel executive
#59

Certainly not, though growth remains something we can keep pushing forward.

Mal Patel executive
#60

I believe we have room for one more question, and it also happens to be the final one on the list here. Would you talk about how you think about capital allocation overall? And more specifically, what would you need to see before you'd start any share buybacks?

Louisa Burdett executive
#61

This aligns with the message we've delivered over the past couple of years. When it comes to allocating capital, our top priority is reinvesting organically into the business and keeping the dividend progressive. Small M&A opportunities still interest us, though large-scale M&A isn't where our focus lies right now. On top of that, we're working to deleverage the balance sheet. Some progress has been made, but naturally we'd want to bring that figure down from 1.8x. We won't be setting a threshold at which we'd alter course and start considering share buybacks. That said, as Nimesh and I have mentioned previously, once we're further along on that journey, we'd be eager to begin that discussion.

Mal Patel executive
#62

Thank you. Louisa, it seems we have no questions left, so I'll turn things over to Nimesh for closing remarks.

Nimesh Patel executive
#63

Thank you. Thanks, Mal. And thanks to all of you for tuning in and for your questions. I suppose the final point I'd like to make is that this set of results gives us all reassurance, and in our view it underscores the quality of our businesses. We feel pleased and confident about what lies within our control as we execute our strategy and as we see the results coming through from that. Our guidance has not been changed, but I think what these results have helped us do is take some risk out of delivery in the second half, though we do recognize that the world remains unpredictable. So we'll keep working hard to make sure we hit guidance for the full year. So thank you, everyone, for joining, and I look forward to speaking with all of you again soon.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Spirax Group plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Spirax Group plc earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.